title: [The indicators of hemostasis and functions of liver in patients with acute lymphoblastic leucosis under manifestation of disease and induction therapy].
abstract: The function of liver and synthesized by it components of blood coagulation were studied on sampling of 25 patients with acute lymphoblastic leucosis in the debut of disease and under implementation of induction of remission. Before treatment the hepatotoxicity was detected in 40% of patients. The reliable correlation between level of aspartataminotransferase and number of leucocytes and blasts (rs = 0.401 and rs = 0.406 correspondingly) testifies the role of leucosis cells in functional disorders of liver during this period of disease. Against the background of cytostatic therapy the signs of liver damage were presented in 76% of patients. The maximum expressed hepatotoxicity was observed at 9-14 day of treatment. The decrease of components of hemostasis synthesized in liver was observed at 16-21 day of treatment. During this time the synthesis of factors of thrombin complex, antithrombin III and plasminogen was disordered. The plasminogen also decreased at the expense of its consumption as a result of fibrinolysis activation validated by decreased level of D-dimers. It is proved that in the debut and under treatment acute lymphoblastic leucosis the danger of development of thrombotic hemorrhagic complications is related both with derangement of synthesis of procoagulants, antithrombin III and plasminogen and with their consumption in case of activation of intravascular coagulation with leucosis process and cytostatic.
authors.forename: L N
authors.initials: LN
authors.lastname: Tarasova
authors.forename: S G
authors.initials: SG
authors.lastname: Vladimirova
authors.forename: O Yu
authors.initials: OY
authors.lastname: Skolskaya
authors.forename: V V
authors.initials: VV
authors.lastname: Tcherepanova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000378:metabolism; D001219:Aspartate Aminotransferases / Q000097:blood; D054697:Cytostatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006487:Hemostasis; D006801:Humans; D060828:Induction Chemotherapy; D007962:Leukocytes / Q000473:pathology; D008099:Liver / Q000473:pathology* / Q000503:physiopathology; D008107:Liver Diseases / Q000097:blood / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D013917:Thrombin / Q000378:metabolism
chemical_list: D054697:Cytostatic Agents; D000990:Antithrombin III; D010958:Plasminogen; D001219:Aspartate Aminotransferases; D013917:Thrombin